+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Ursodeoxycholic acid udca treatment improves liver disease and nutritional state in cystic fibrosis cf patients with chronic cholestasis



Ursodeoxycholic acid udca treatment improves liver disease and nutritional state in cystic fibrosis cf patients with chronic cholestasis



Gastroenterology 96(5 Part 2): A586




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034144960

Download citation: RISBibTeXText


Related references

Amelioration of cholestasis and nutritional state in patients with cystic fibrosis cf treated with ursodeoxycholic acid udca. Journal of Hepatology 9(Suppl. 1): S21, 1989

The effect of ursodeoxycholic acid udca on liver function and bile acid metabolism in patients with cystic fibrosis cf and liver disease. Hepatology 10(4): 726, 1989

Ursodeoxycholic acid udca therapy in patients with cystic fibrosis cf and liver disease a dose response study. Gastroenterology 100(5 Part 2): A731, 1991

Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. Journal of Pediatrics 121(1): 138-141, 1992

Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 31(8): 918-921, 1990

Ursodeoxycholic acid udca decreases serum cholesterol levels ameliorates symptoms and improves biochemical parameters in pediatric patients with chronic intrahepatic cholestasis. Gastroenterology 98(5 Part 2): A566, 1990

Ursodeoxycholic acid improves cholestasis in infants with cystic fibrosis. Annals of PharmacoTherapy 31(9): 1003-1005, 1997

Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 23(6): 1484-1490, 1996

Treatment with ursodeoxycholic acid for patients with cystic fibrosis and liver disease. Escobar, H, Baquero, F, Suarez, L International Congress Series; Clinical ecology of cystic fibrosis 275-279, 1993

Toxicity of ursodeoxycholic acid udca in chronic cholestasis assessed by quantitative liver function tests. Journal of Hepatology 7(Suppl. 1): S54, 1988

Safety evaluation of ursodeoxycholic acid udca in patients with chronic cholestasis. Naunyn-Schmiedeberg's Archives of Pharmacology 339(Suppl.): R119, 1989

Markedly decreased biliary ursodeoxycholic acid enrichment with high dose UDCA in cystic fibrosis associated liver disease Optimization of the therapeutic dose. Hepatology 20(4 Part 2): 262A, 1994

Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease. Digestive and Liver Disease 42(6): 428-431, 2010

Clinical outcome of long-term treatment of ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Paumgartner, G, Stiehl, A, Gerok, W Falk Symposium; Bile acids in hepatobiliary diseases: Basic research and clinical application 318-322, 1997

Supplementation of ursodeoxycholic acid improves fat digestion and absorption in cystic fibrosis patients with mild liver involvement. European Journal of Gastroenterology & Hepatology 28(6): 645-649, 2016